Writing Group for the Women's Health Initiative Investigators's scientific contributions

Citations

... This highlights the importance of developing new antiprogestins with high specificity and lower toxicity than those currently available. The fact that progestins have been shown to increase breast cancer risk [187,188], and that antiprogestins, such as MFP, were shown to act as PR agonists in PRB contexts [189] may be some of the reasons to explain the hampered interest in PR ligands. Nowadays, the attention has been focused on exploring new targets that might be used together with standard endocrine therapy. ...